A direct correlation between nicotinamide N-methyltransferase activity and protein levels in human liver cytosol.
暂无分享,去创建一个
M. L. Smith | A. Williams | R. Waring | D. Burnett | D. Ramsden | P. Bennett | H. Brown
[1] R. Weinshilboum,et al. Mouse liver nicotinamide N-methyltransferase: cDNA cloning, expression, and nucleotide sequence polymorphisms. , 1997, Biochemical pharmacology.
[2] D. Jenden,et al. Elevation of cerebrospinal fluid choline levels by nicotinamide involves the enzymatic formation of N1-methylnicotinamide in brain tissue. , 1996, Life sciences.
[3] P. Lance,et al. n‐Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells , 1996, Hepatology.
[4] P. Little,et al. Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. , 1995, Genomics.
[5] K. Kawajiri,et al. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region. , 1994, Journal of biochemistry.
[6] R. Weinshilboum,et al. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. , 1994, The Journal of biological chemistry.
[7] A. Jones,et al. The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein. , 1993, The Biochemical journal.
[8] R. Stockley,et al. Use of an enzyme-linked immunosorbent assay to assess penetration of amoxicillin into lung secretions , 1992, Antimicrobial Agents and Chemotherapy.
[9] D. Nebert,et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. , 1991, American journal of human genetics.
[10] R. Weinshilboum,et al. Thiopurine methyltransferase isozymes in human renal tissue. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[11] D. Grant,et al. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. , 1990, The Journal of clinical investigation.
[12] C. Szumlanski,et al. Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. , 1990, Clinica chimica acta; international journal of clinical chemistry.
[13] R. Weinshilboum. Pharmacogenetics of methylation: relationship to drug metabolism. , 1988, Clinical biochemistry.
[14] T. Alston,et al. Substrate specificity of nicotinamide methyltransferase isolated from porcine liver. , 1988, Archives of biochemistry and biophysics.
[15] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[16] A. J. Bradbury,et al. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety , 1985, Neuroscience Letters.
[17] A. J. Bradbury,et al. The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment , 1985, Neuroscience Letters.
[18] G. Cantoni. Methylation of nicotinamide with soluble enzyme system from rat liver. , 1951, The Journal of biological chemistry.
[19] R. Weinshilboum,et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.
[20] R. Cuomo,et al. Nicotinamide methylation in patients with cirrhosis. , 1994, Journal of hepatology.
[21] H. Pall,et al. N-methylation of pyridines and Parkinson's disease. , 1993, Advances in neurology.
[22] E. Harlow,et al. Antibodies: A Laboratory Manual , 1988 .